CLINUVEL PHARMACEUTICALS LIMITED
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CLINUVEL PHARMACEUTICALS LIMITED
Finance Watch: VC Mega-Rounds Make A Comeback In March
Private Company Edition: After just seven venture capital rounds of $100m or more in January and February, five have been announced already in March, including a $200m series A round for Cargo Therapeutics, Chroma Medicine’s $135m series B financing and $112m for Noema’s series B.
Deal Watch: Adaptimmune, TCR2 Join Forces As Cell Therapy Company Focused On Solid Tumors
All-stock merger will create new company owned 75% by Adaptimmune’s shareholders. Grifols, Selagine to explore antibody approach to treating dry eye disease, and other recent deals.
Clinuvel Plots Competition To Incyte In Vitiligo Space
The Australian company is steadily growing its photoprotective drug in adults with erythropoietic protoporphyria but also sees a big opportunity in the pigment loss disorder.
Incyte Bolsters Dermatology Ambitions With Vitiligo Approval For Topical Ruxolitinib
Opzelura, already approved for atopic dermatitis, gives Incyte a second indication for its topical JAK inhibitor. It is the first treatment approved for vitiligo.
- Specialty Pharmaceuticals
- Site Specific
- Large Molecule
- Other Names / Subsidiaries
- Vallaurix Pte Ltd
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.